Preclinical activity of the novel B‐cell‐specific Moloney murine leukemia virus integration site 1 inhibitor PTC‐209 in acute myeloid leukemia: Implications for leukemia therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|12|1705-1713

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.12, 2015-12, pp. : 1705-1713

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia

By  

Cancer Science, Vol. 106, Iss. 11, 2015-11 ,pp. : 1590-1595

John Wiley & Sons Inc

Access to resources Recommend Favorite

Human T‐cell leukemia virus type 1 Tax oncoprotein represses the expression of the BCL11B tumor suppressor in T‐cells

By  

Cancer Science, Vol. 106, Iss. 4, 2015-04 ,pp. : 461-465

John Wiley & Sons Inc

Access to resources Recommend Favorite

Advanced human T‐cell leukemia virus type 1 carriers and early‐stage indolent adult T‐cell leukemia‐lymphoma are indistinguishable based on CADM1 positivity in flow cytometry

By  

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 598-603

John Wiley & Sons Inc

Access to resources Recommend Favorite

Expression profile analysis of long non‐coding RNA in acute myeloid leukemia by microarray and bioinformatics

By  

Cancer Science, Vol. 109, Iss. 2, 2018-02 ,pp. : 340-353

John Wiley & Sons Inc

Access to resources Recommend Favorite

Potential roles of microRNA‐29a in the molecular pathophysiology of T‐cell acute lymphoblastic leukemia

By  

Cancer Science, Vol. 106, Iss. 10, 2015-10 ,pp. : 1264-1277

John Wiley & Sons Inc

Access to resources Recommend Favorite